Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 1, Pages 117-133Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.09.004
Keywords
Enzyme based therapy; Enzyme; Therapy; Biologic; Therapeutic enzymes; Clinical; Pre-clinical; Early investigational; Biotechnology; History
Categories
Funding
- North Carolina Biotechnology Center [2018-BIG-6503]
- NIH Biotechnology Training Grant [T32GM008555]
- NIH [R61 AI140485-01]
Ask authors/readers for more resources
Enzyme-based therapeutics have the potential to tap into vast enzyme biodiversity and treat various conditions, but face challenges in the development of new therapies, including overcoming technical barriers.
Enzyme-based therapeutics (EBTs) have the potential to tap into an almost unmeasurable amount of enzyme biodiversity and treat myriad conditions. Although EBTs were some of the first biologics used clinically, the rate of development of newer EBTs has lagged behind that of other biologics. Here, we review the history of EBTs, and discuss the state of each class of EBT, their potential clinical advantages, and the unique challenges to their development. Additionally, we discuss key remaining technical barriers that, if addressed, could increase the diversity and rate of the development of EBTs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
